We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
pSivida Receives First R&D Payments from Pfizer
News

pSivida Receives First R&D Payments from Pfizer

pSivida Receives First R&D Payments from Pfizer
News

pSivida Receives First R&D Payments from Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "pSivida Receives First R&D Payments from Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

pSivida Limited has announced the receipt of US$500k as the first quarterly research and development payment from Pfizer under the terms of the exclusive worldwide Collaborative Research and License Agreement signed in April 2007 for pSivida’s controlled drug delivery technologies in ophthalmic applications.

Over the last 10 months pSivida has received US$12m from Pfizer, including equity investments, under the terms of that agreement and will receive up to an additional US$153.5m in development and sales related milestones. Pfizer is the largest shareholder in Company holding approximately 10% of the outstanding shares.

“We are very pleased that the Pfizer licensing agreement is proceeding as expected,” said pSivida’s Managing Director, Dr Paul Ashton.

Advertisement